Search results for "Hypolipidemic effect"
showing 3 items of 3 documents
LC-ESI/HRMS analysis of glucosinolates, oxylipins and phenols in Italian rocket salad (Diplotaxis erucoides subsp. erucoides (L.) DC.) and evaluation…
2021
BACKGROUND: This study investigated the chemical profile and biological activity of Diplotaxis erucoides subsp. erucoides (L.) DC. (Brassicaceae) collected in Sicily (Italy). RESULTS: Liquid chromatography coupled with electrospray ionization and high-resolution mass spectrometry (LC-ESI/HRMS) analysis of the ethanol extract revealed the presence of 42 compounds – glucosinolates, hydroxycinnamic acids, flavonoids, and oxylipins. The extract was tested for its antioxidant activity using 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic) acid (ABTS), ferric reducing ability power (FRAP), and β-carotene bleaching tests. Promising protection from lipid peroxi…
Therapeutic effect of fractionated by ultrafiltration red beetroot (Beta vulgaris l.) juice in rats with food-induced fatty liver
2019
The prevalence of non-alcoholic fatty liver disease (NAFLD), being a component of metabolic syndrome, has increased (15-27%) in the industrialized world. The deep mechanism of this pathology is not clear, but it is multifactorial. There is a huge amount of food supplements and medicines with hepatoprotective effect on the market, but the NAFLD problem is far from being resolved. Hepatoprotective products have to provide wide spectra of biological effects, including antioxidant, hypolipidemic, anti-inflammatory action. It is peculiar to natural compounds, including red beetroot juice, which is well known to most of the population. This is important in view of the high prevalence of NAFLD. Th…
Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo
2018
Source at https://doi.org/10.3389/fmicb.2018.00530 . Background: Statin has been widely used to treat hyperlipidemia because of its high potency in decreasing cholesterol levels. The present study aimed to examine the lipid-lowering effect of rosuvastatin and the composition, diversity and species abundance of gut microbiome in association with rosuvastatin efficacy. TRIAL REGISTRATION: ChiCTR-ORC-17013212 at the First Affiliated Hospital of Dalian Medical University, November 2, 2017. Results:Totally 64 patients with hyperlipidemia were treated with 10 mg/day of rosuvastatin for 4-8 weeks. Blood lipid indicators triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), lo…